Gene therapy strategies for the treatment of cancer. A review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Vnencak-Jones C. Molecular testing for inherited diseases. Am J Clin Pathol 1999; 112 (Supl 1): 19–32.
Crystal R. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404–410.
Hahn W, Counter C, Lundberg A, Beijersbergen R, Brooks M, Weinberg R. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464–468.
Ilyas M, Straub J, Tomlinson I, Bodmer W. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999; 35: 335–351.
Cole-Strauss A, Yoon K, Xiang Y, Byrne B, Rice M, Gryn J et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 1996; 273: 1386–1389.
Kren B, Bandyopadhyay P, Steer C. In vivo site-directed mutagenesis of the factor IX by chimeric RNA/DNA oligonucleotides. Nat Med 1998; 4: 285–290.
Templeton N, Lasic D, Frederik P, Strey H, Roberts D, Pavlakis G. Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997; 15: 647–652.
Doe B, Selby M, Barnett S, Baezinger J, Walker C. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA 1996; 93: 8578–8583.
Rols M, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998; 16: 168–171.
Rakhmilevich A, Turner J, Ford M, McCabe D, Sun W, Sondel P et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 6291–6296.
Plank C, Tang MX, Wolfe AR, Szoka FC Jr. Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum Gene Ther 1999; 10: 319–332.
Kollen WJ, Mulberg AE, Wei X, Sugita M, Raghuram V, Wang J et al. High-efficiency transfer of cystic fibrosis transmembrane conductase regulator cDNA into cystic fibrosis airway cells in culture using lactosylated polylysine as a vector. Hum Gene Ther 1999; 10: 615–622.
Ziady A, Ferkol T, Gerken T, Dawson D, Perlmutter, D Davis P. Ligand substitution of receptor targeted DNA complexes affects gene transfer into hepatoma cells. Gene Ther 1998; 5: 1685–1697.
Erbacher P, Remy J, Behr J. Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway. Gene Ther 1999; 6: 138–145.
Peng K, Vile R. Vector development for cancer gene therapy. Tumor Targeting 1999; 4: 3–11.
Schwarzenberger P, Hunt J, Robert E, Theodossiou C, Rolls J. Receptor-targeted recombinant adenovirus conglomerates: a novel molecular conjugate vector with improved expression characteristics. J Virol 1997; 71: 8563–8571.
Cristiano R, Smith L, Kay M, Brinkley B, Woo S. Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenvirus-DNA complex. Proc Natl Acad Sci USA 1993; 90: 11548–11552.
Kaneda Y. Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. Mol Membr Biol 1999; 16: 119–122.
Roth J, Cristiano R. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997; 89: 21–39.
Dranoff G. Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol 1998; 16: 2548–2556.
Amado R, Chen I. Lentiviral vectors-the promise of gene therapy within reach? Science 1999; 285: 674–676.
Markowitz D, Hesdorffer C, Ward M, Goff S, Bank A. Retroviral gene transfer using safe and efficient packaging cell lines. Ann NY Acad Sci 1990; 612: 407–414.
Nguyen T, Pages J, Farge D, Briand P, Weber A. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum Gene Ther 1998; 9: 2469–2479.
Hardy S, Kitamura M, Harris-Stansil T, Dai, Y Phipps M. Construction of adenovirus through Cre-lox recombination. J Virol 1997; 71: 1842–1849.
Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin gene. Proc Natl Acad Sci USA 1998; 95: 7866–7871.
Miller C, Buchsbaum D, Reynolds P, Douglas J, Gillespie G, Mayo M et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738–5748.
Douglas J, Rogers B, Rosenfeld M, Michael S, Feng M, Curiel D. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574–1578.
Gu D, Gonzalez A, Printz M, Doukas J, Ying W, D’Andrea M et al. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res 1999; 59: 2608–2614.
Vanderkwaak T, Wang M, Gomez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999; 74: 227–234.
Han J, Qian D, Wicha M, Clarke M. A method of limited replication for the efficient in vivo delivery of adenovirus to cancer cells. Hum Gene Ther 1998; 9: 1209–1216.
Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenoviurs (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559–2563.
Yu D, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human Kallikrein 2 and their use in the construction of Calydon Virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59: 1498–1504.
Yu D, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200–4203.
Hallenbeck P, Chang Y, Hay C, Golightly D, Stewart D, Lin J et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721–1733.
Bischoff J, Kirn D, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.
Rothmann T, Hengstermann A, Whitaker N, Scheffner M, Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470–9478.
Hay J, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom W. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the Elb-55kD gene. Hum Gene Ther 1999; 10: 579–90.
Heise C, Williams A, Xue S, Propst M, Kirn D. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999; 59: 2623–2628.
Kirn D, Hermiston T, McCormick F. ONYX-015: Clinical data are encouraging. Nat Med 1998; 4: 1341–1342.
Wildner O, Blaese R, Morris J. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410–413.
Shinoura N, Yoshida Y, Tsunoda R, Ohashi M, Zhang W, Asai A et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res 1999; 59: 3411–3416.
Velculescu V, Zhang L, Vogelstein B, Kinzler K. Serial analysis of gene expression. Science 1995; 270: 484–487.
Hart I. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 1996; 23: 154–158.
Gotoh A, Ko S, Shirakawa T, Cheon J, Kao C, Miyamoto T et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 1998; 160: 220–229.
Lan K, Kanai F, Shiratori Y, Makoto O, Tanaka T, Okudaira T et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res 1997; 57: 4279–4284.
Cao G, Kuriyama S, Gao J, Kikukawa M, Cui L, Nakatani T et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther 1999; 6: 83–90.
Kanai F, Lan K, Shiratori Y, Tanaka T, Ohashi M, Okudaira T et al. In vivo gene therapy for a-Fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57: 461–465.
Cheon J, Ko S, Gardner T, Shirakawa T, Gotoh A, Kao C et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther 1997; 4: 359–365.
Dachs G, Patterson A, Firth J, Ratcliffe P, Townsend K, Stratford I et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515–520.
Parr M, Manome Y, Tanaka T, Wen P, Kufe D, Kaelin WJ et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997; 3: 1145–1149.
Katabi M, Chan H, Karp S, Batist G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Hum Gen Ther 1999; 10: 155–164.
Massuda E, Dunphy E, Redman R, Schreiber J, Nauta L, Barr F et al. Regulated expression of the diphteria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells. Proc Natl Acad Sci USA 1997; 94: 14701–14706.
Connors T. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 1995; 2: 702–709.
Ram Z, Culver K, Oshiro E, Viola J, DeVroom H, Otto E et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vectro-producing cells. Nat Med 1997; 3: 1354–1361.
Bi W, Parysek L, Warnick R, Stambrook P. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725–731.
Nanni P, DeGiovanni C, Nicoletti G, Landuzzi L, Rossi I, Frabetti F et al. The immune response elicited by mammary adenocarcinoma cells transduced with interferongamma and cytosine deaminase genes cures lung metastases by parental cells. Hum Gene Ther 1998; 9: 217–224.
Cao X, Ju D, Tao Q, Wang J, Wan T, Wang B et al. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine admininstration elicit more potent antitumor response in tumorbearing mice. Gene Ther 1998; 5: 1130–1136.
Mullen C, Coale M, Lowe R, Blaese R. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 1994; 54: 1503–1506.
Chen L, Waxman D. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581–589.
Bailey S, Knox R, Hobbs S, Jenkins T, Mauger A, Melton R et al. Investigation of alternative prodrugs for use with E. coli nitroreductase in “suicide gene” approaches to cancer therapy. Gene Ther 1996; 3: 1143–1150.
Freytag S, Rogulski K, Paielli D, Gilbert J, Kim J. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Human Gene Ther 1998; 9: 1323–1333.
Rogulski K, Zhang K, Kolozsvary A, Kim J, Freytag S. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 1997; 3: 2081–2088.
Maas R, Dullens H, Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 1993; 36: 141–148.
Addison C, Bramson J, Hitt M, Muller W, Gauldie J, Graham F. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 1998; 5: 1400–1409.
Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsky H, Simons J et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of antitumor response. Cell 1990; 60: 397–403.
Golumbek P, Lazenby A, Levistky H, Jaffee L, Karasuyama H, Baker M et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716.
Rosenberg S, Aebersold P, Cornetta K, Kasid A, Morgan R, Moen R et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–578.
Merrouche Y, Negrier S, Bain C, Combaret V, Mercatello A, Coronel B et al. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 1995; 13: 410–408.
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543.
Simons J, Jaffee E, Weber C, Levitsky H, Nelson W, Carducci M et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocy-te-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537–1546.
Putzer B, Hitt M, Muller W, Emtage P, Gauldie J, Graham F. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 1997; 94: 10889–10894.
Specht J, Wang G, Do M, Lam J, Royal R, Reeves M et al. Dendritic cells retrovirally transduced with a model antigen are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186: 1213–1221.
Boczokowski D, Nair S, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465–472.
Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594–600.
Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 1999; 6: 63–73.
Janus F, Albrechsten N, Dornreiter I, Wiesmuller L, Grosse F, Deppert W. The dual role of p53 in maintaining genomic integrity. Cell Mol Life Sci 1999; 55: 12–27.
Harris M, Sutjipto S, Wills K, Hancock W, Cornell D, Johnson D et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996; 3: 121–130.
Xu M, Kumar D, Srinivas L, De Tolla L, Yu S, Stass S et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 1996; 8: 177–185.
Bouvet M, Ellis L, Nishizaki M, Fujiwara T, Liu W, Bucana C et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998; 58: 2288–2292.
Miyashita T, Reed C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–299.
Swisher S, Roth J, Nemunaitis J, Lawrence D, Kemp B, Carrasco C et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763–771.
Schuler M, Rochlitz C, Horowitz J, Schlegel J, Perruchoud A, Kommoss F et al. A phase I study of adenovi-rus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998; 9: 2075–2082.
Badie B, Goh C, Klaver J, Herweijer H, Boothman D. Combined radiation and p53 9 gene therapy of malignant glioma cells. Cancer Gene Ther 1999; 6: 155–162.
Vinyals A, Peinado M, Gonzalez-Garrigues M, Monzo M, Bonfil R, Fabra A. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther 1999; 6: 22–33.
Dorigo O, Turla S, Lebedeva S, Gjerset R. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg 1998; 88: 535–540.
Wolf J, Kim T, Fightmaster D, Bodurka D, Gershenson D, Mills G et al. Growth suppression of human ovarian cancer cell lines by the introduction of a p 16 gene via a recombinant adenovirus. Gynecol Oncol 1999; 73: 27–34.
Nikitin A, Juarez-Perez M, Li S, Huang L, Lee W. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/-mice. Proc Natl Acad Sci USA 1999; 96: 3916–3921.
Bos J. All in the family? New insights and questions regarding interConnectivity of Ras, Rap 1 and Ra1. EMBO J 1998; 17: 6776–6782.
Mangues R, Corral T, Kohl N, Symmans W, Lu S, Malumbres M et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 1998; 58: 1253–1259.
Kita K, Saito S, Morioka C, Watanabe A. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 1999; 80: 553–558.
Feng M, Cabrera G, Deshane J, Scanlon K, Curiel D. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55: 2024–2028.
Cochet O, Kenigsberg M, Delumeau I, Virone-Oddos A, Multon M, Fridman W et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res 1998; 58: 1170–1176.
Webb A, Cunningham D, Cotter F, Clarke P, DiStefano F, Ross P et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137–1141.
Ealovenga M, McGinnis P, Sumantran V, Clarke M, Wicha M. Bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res 1996; 56: 1965–1969.
Clarke M, Apel I, Benedict M, Eipers P, Sumantran V, Gonzalez-Garcia M et al. A recombinant bcl-xs adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci USA 1995; 92: 11024–11028.
Tai Y, Strobel T, Kufe D, Cannistra S. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the Bax gene. Cancer Res 1999; 59: 2121–2126.
Kondo S, Kondo Y, Li G, Silverman R, Cowell J. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998; 16: 3323–3330.
Fang K, Chen M. Transfection of anti-sense complementary DNA of human epidermal-growth-factor receptor attenuates the proliferation of human non-small-cell-lung-cancer cells. Int J Cancer 1999; 81: 471–478.
Crystal R. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother Pharmacol 1999; 43 (Supl): 90-S99.
Chen Q, Kumar D, Stass S, Mixson A. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999; 59: 3308–3312.
Coffey M, Strong J, Forsyth P, Lee P. Reovirus therapy of tumors with an activated ras pathway. Science 1998; 282: 1332–1334.
Monroe W, McQuain M, Chang M, Alexander J, Haselton F. Targeting expression with light using caged DNA. J Biol Chem 1999; 274: 20895–20900.
Blackburn R, Galaforo S, Corry P, Lee Y. Adenoviralmediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res 1998; 58: 1358–1362.
Nagayama Y, Nishihara E, Iitaka M, Namba H, Yamashita S, Niwa M. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-1oxP system. Cancer Res 1999; 59: 3049–3052.
Pirollo K, Hao Z, Rait A, Jang Y, Fee WJ, Ryan P et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735–1746.
Sánchez-Prieto R, Quintanilla M, Cano A, Leonart M, Martín P, Anaya A et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1a gene. Oncogene 1996; 13: 1083–1092.